|
|
| Growth Hormone | ||
| Order Code: HGH
Order Form: A-1a Miscellaneous Request or IPR Req |
Commercial "Mail-out" Laboratory 6240 RCP 356-3527 |
|
Specimen |
Serum or Plasma | ||
Collection Medium: |
| ||
Alternate Collection Media: |
Light Green top tube (Lithium Heparin), Green top tube (Na Heparin), Lavender top tube (EDTA), Pink top tube (EDTA sprayed) | ||
Minimum: |
Adult recommended minimum: 1.0 ml serum or plasma Adult absolute minimum: 0.4 ml serum or plasma Pediatric absolute minimum: 0.4 ml serum or plasma If additional tests are going to be ordered, extra red top tubes may be needed. Please call the lab for consultation. | ||
Analytic Time: |
4 working days | ||
Reference Range: |
Male: 0-6 years: 0.10-8.80 ng/mL 7-17 years: 0.03-14.90 ng/mL 18 years and older: 0.01-1.00 ng/mL Female: 0-6 years: 0.10-8.80 ng/mL 7-17 years: 0.06-23.80 ng/mL 18 years and older: 0.03-10.00 ng/mL | ||
Test Limitations: |
Human growth hormone (GH, hGH, Somatotropin) is composed of a single polypeptide chain of 191 amino acids and is structurally similar to prolactin and placental lactogen. GH is produced in and released from the acidophilic cells of the anterior pituitary gland. Basal levels of GH in normal individuals are usually less than 2 ng/mL and are stable throughout the day. Normal elevations in GH occur following meals, after exercise, and during sleep. Children who fail to grow at the expected rate and who have short stature with apparent normal body proportions often have a diminished capacity to secrete growth hormone. If the child may be short because of growth hormone deficiency, insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) should be the first screening tests. When growth hormone deficiency is marked, the diagnosis is relatively easy to confirm, as affected children present with severe growth failure, delayed bone age, and very low serum concentrations of growth hormone, IGF-1, and IGFBP-3. These children may have an isolated trophic hormone deficiency. The diminished capacity to secrete hGH may also result from a hypothalamic or hypophyseal lesion involving more than one releasing factor or trophic hormone. The deficiency may be either congenital or acquired. Children who have hypothyroidism may fail to have normal growth hormone release; therefore, growth hormone testing should be done only after a euthyroid state is induced by appropriate treatment. Growth hormone deficiency in both adults and children may be the direct result of neoplastic or infiltrative disease of the pituitary. It may also follow cranial irradiation for brain tumors and other neoplasms. In patients with intracranial lesions involving the hypothalamus or pituitary, growth hormone values may be useful in evaluating the extent or progression of such lesions. The demonstration of elevated and unsuppressible serum growth hormone levels following glucose administration helps to confirm the diagnosis in adults with signs and symptoms of acromegaly and more rarely in children or adolescents with gigantism. After a glucose tolerance test, GH should suppress to less than 2 ng/mL, but fails to do so in patients with acromegaly. The following tests -- Arginine Infusion, Insulin Tolerance, Combined Arginine- Insulin Infusion, L-dopa, Glucagon, Clonidine Simulation (not considered a reliable test for adults), Sleep-Induced GH Secretion, and Exercise-Induced GH Secretion -- should induce a peak GH value greater than 7 ng/mL in children and greater than 5 ng/mL in adults; lower values suggest deficiency. However, a recent consensus conference recommended that a peak GH during insulin tolerance testing of less than 3 ng/mL for the diagnosis of GH deficiency in adults be consulted. For children, some experts consider values of 7-10 ng/mL equivocal and only peak values of greater than 10 ng/mL as truly normal. For suppression testing, normal subjects have growth hormone concentrations of less than 1 ng/mL within two hours of ingestion of a 75 or 100 gram glucose dose. Patients with acromegaly fail to show normal suppression. | ||
Methodology: |
Chemiluminescent Immunoassay | ||
CPT Code: |
83003 |
Updated: 05/16/2007
Note: The information contained in this handbook is for use by personnel of University of Iowa Health Care. No other use is implied or intended.